Loading clinical trials...
Loading clinical trials...
An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days
Conditions
Interventions
3% w/w SPL7013 Gel
Placebo
Locations
2
United States
University of California San Francisco
San Francisco, California, United States
Kenya Medical Research Institute
Kisumu, Kenya
Start Date
December 1, 2006
Primary Completion Date
November 1, 2007
Completion Date
November 1, 2007
Last Updated
August 23, 2013
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions